Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


BioMarin Pharmaceuticals



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, BioMarin Pharmaceuticals rose 45 cents (1.2%) to $38.35 on average volume. Throughout the day, 1.6 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $37.69-$38.57 after having opened the day at $37.85 as compared to the previous trading day's close of $37.90. Other companies within the Drugs industry that increased today were:

Peregrine Pharmaceuticals



), up 26.7%,

Bacterin International Holdings



), up 17.8%,

Rexahn Pharmaceuticals


Scroll to Continue

TheStreet Recommends


), up 16%, and

Opexa Therapeutics



), up 15.9%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.78 billion and is part of the

health care

sector. Shares are up 12.6% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the negative front,

Catalyst Pharmaceutical Partners



), down 19.6%,

Senesco Technologies



), down 12%,

Ampio Pharmaceuticals



), down 9.6%, and

Skystar Bio-Pharmaceutical Company



), down 8.8%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech